High burden of antimicrobial resistance among gram negative bacteria causing healthcare associated infections in a critical care unit of Nepal

Narayan Prasad Parajuli¹,², Subhash Prasad Acharya³, Shyam Kumar Mishra¹, Keshab Parajuli¹, Basista Prasad Rijal¹ and Bharat Mani Pokhrel¹

Abstract

Background: Healthcare associated infections (HCAI) and antimicrobial resistance are principal threats to the patients of intensive care units and are the major determining factors for patient outcome. They are associated with increased morbidity, mortality, excess hospitalization and financial costs. The present study is an attempt to investigate the spectrum and antimicrobial resistance of bacterial isolates involved in healthcare associated infections (HCAI) in the patients of a critical care unit at a tertiary care university hospital in Kathmandu, Nepal.

Methods: A laboratory based study was conducted over the period of 15 months (January 2014 to March 2015) among the patients of intensive care unit of Tribhuvan University Teaching Hospital, Kathmandu, Nepal. Clinical specimens from patients with suspected healthcare-associated infection were processed and bacterial isolates were identified with standard microbiological methods. Antimicrobial susceptibilities of the isolated strains were determined according to the CLSI guidelines and β-lactamases (ESBL, AmpC, MBL and KPC) were detected by various phenotypic tests.

Results: One hundred and forty nine clinical specimens received from 135 patients suspected of HCAI (out of 491 patients) were found with significant bacterial growth. Specimens were from patients suspected of hospital-acquired pneumonia (16%, 79/491), bloodstream infections (5.7%, 28/491), surgical site infections (4.7%, 23/491), and urinary tract infections (3.9%, 19/491). Acinetobacter spp., Klebsiella spp., Escherichia coli and Burkholderia cepacia were the leading bacterial pathogens. Extremely high level of drug resistance (95.8%) along with the production of β-lactamases (ESBL; 43.7%, AmpC; 27.5%), MBL; 50.2% and KPC; 4.2%) was observed among Gram negative bacterial isolates.

Conclusion: Healthcare associated infections are very common in our ICU. Gram negative bacterial pathogens are major culprits associated with these infections and there is alarming state of drug resistance among these isolates. Continuous surveillance and establishment of preventive and control measures of healthcare associated infections are urgently needed in our setting.

Keywords: Healthcare associated infections, ICU, MDR bacteria, β-lactamases, Nepal
Background

Infection is the most common presentation among hospitalized patients of intensive care unit (ICU), and in many instances, is a determining factor for patient outcomes [1, 2]. Healthcare associated infections (HAIs), in particular, are the major risks associated with critically ill patients of ICU, due to the reduced host defenses, frequent use of invasive medical devices, administration of multiple drugs, cross transmission of pathogens among patients and staffs, and inadequate infection control procedures [3, 4]. Hence, intensive care units (ICUs) are now often recognized as the epicenter of infections in the hospital [5]. Pneumonia, surgical-site infections, catheter-related bloodstream infections and urinary tract infections are currently the most common cause of death in ICU due to healthcare associated infections [6]. According to a large surveillance study, more than 70% of critically ill patients receive an antimicrobial drug during their ICU stay either for prophylaxis or for therapy [1]. Nevertheless, in the recent years, therapeutic drugs are being progressively ineffective against bacterial infections, threatening the success of routine treatment [7]. The major consequences of this problem are increased patient morbidity, mortality, health care related expenses and treatment failure [8, 9].

$\beta$-lactam antibiotics are the major bulk of prescribed antibiotics in ICUs across the globe because of their efficacy, broad spectra and low toxicity [10]. However, irrational use of these antibiotics has resulted in the development and spread of drug resistant bacterial pathogens especially in the developing countries [11]. Of the particular concern, increased occurrence of Gram negative bacteria, including multidrug resistant nonfermenters (Acinetobacter baumannii and Pseudomonas species) and Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBL) and carbapenemases in severe healthcare-associated infections has evolved as a significant clinical threat for medical fraternity in the recent decades [12, 13]. The broad substrate profile of these enzymes may affect entire beta lactam agents, and also the organisms with these enzymes are additionally found resistant to aminoglycosides and fluoroquinolones, further compromising the therapeutic choices for severe infections in ICU [14, 15].

In Nepal, international guidelines on initial antibiotic selection are generally applied in ICUs and empiric choices are made for serious ICU related infections. Thorough knowledge of epidemiology, spectrum and nature of infections along with susceptibilities of causative organisms are extremely valuable for empirical treatment of severe infections in intensive care hospital settings. Therefore, it would be an effective measure for policy formulation of judicious antimicrobial therapy for critically ill patients in the intensive care units of various hospitals in our country. In this perspective, we aimed to determine the incidence of multidrug resistant bacteria, their susceptibilities and common mechanisms of drug resistance involved in healthcare associated infections in the critically ill patients of an intensive care unit at a tertiary care teaching hospital in Kathmandu, Nepal.

Methods

A laboratory based study was conducted at the department of clinical microbiology of the Tribhuvan University Teaching Hospital in Kathmandu, Nepal from January 2014 to March 2015 (over a period of 15 months). All clinical specimens from the patients suspected of healthcare associated infections (after 48 h of admission to the ICU) representing various body systems viz. blood, urine, endotracheal aspirate (ETA), bronchoalveolar lavage fluid (BAL), pleural fluid, pus, peritoneal fluid, cerebrospinal fluid (CSF), CSF shunt, central venous catheter (CVC) etc. were included in the study. The specimens were collected appropriately by trained ICU nurses and transported to the clinical microbiology laboratory with minimal time delay. Specimens that strictly met the criteria recommended by the American Society for Microbiology (ASM) [16] were selected for further processing and analysis. However, specimens not fulfilling the ASM criteria and duplicate specimens from the same patient were excluded.

Inoculation of the specimen and identification of the isolates

The clinical specimens were inoculated onto suitable culture medium according to their specific requirements. Respiratory specimens and CSF samples were cultured on Chocolate agar (CHA), 5% Sheep Blood Agar (BA) and MacConkey Agar (MA) (HiMedia, Mumbai, India) plates. Blood specimens were first enriched with Brain Heart Infusion broth (BHI) and then subcultured on to the 5% Sheep Blood Agar (BA) and MacConkey Agar (MA) (HiMedia, Mumbai, India) plates. The vascular catheter tips (CVC tips) were inoculated onto 5% Sheep blood Agar (BA), MacConkey agar (MA) (HiMedia Mumbai, India) plates. The vascular catheter tips (CVC tips) were inoculated onto 5% Sheep blood Agar (BA), MacConkey agar (MA) (HiMedia Mumbai, India). The plates were incubated in a CO$_2$ incubator (10% CO$_2$) at 37 °C for 24 h. The BA and MA plates were incubated at 37 °C for 24 h in an aerobic atmosphere. Identification of significant isolates that are associated with healthcare associated infections was performed following standard microbiological techniques which involved morphological appearance of the colonies; Gram’s staining, catalase test, coagulase test, oxidase test with other biochemical parameters [16]. Assurance of pure culture
Antibiotic susceptibility testing

The susceptibility of bacterial isolates against different antibiotics was determined by the disk diffusion method [modified Kirby-Bauer method] on Mueller Hinton agar (Hi-Media, India) following standard procedures recommended by the Clinical and Laboratory Standards Institute (CLSI), Wayne, USA [18]. For this purpose following antibiotics with specified concentrations were used: ampicillin (10 µg), ampicillin-sulbactam (10/10 µg), ceftazidime (30 µg), ceftriaxone (30 µg), cefepime (30 µg), cefoxitin (30 µg), piperacillin-tazobactam (100/10 µg, aztreonam (30 µg), imipenem (10 µg), meropenem (10 µg), gentamicin (10 µg), amikacin (30 µg), ciprofloxacin (5 µg), ofloxacin (5 µg), levofloxacin (5 µg), trimethoprim-sulphamethoxazole/co-trimoxazole (25 µg), polymyxin B (300 unit), colistin sulphate (10 µg) and tigecycline (30 µg) from HiMedia Laboratories, India. Interpretations of antibiotic susceptibility results were made according to the guidelines of interpretative zone diameters of CLSI [18]. Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as the control organisms for antibiotic sensitivity.

Identification of Multidrug Resistant (MDR), Extensively Drug Resistant (XDR) and Pan Drug Resistance (PDR) isolates

Multidrug resistant (MDR) bacterial isolates were identified according to the criteria recommended by international expert committee of the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) [19]. In this study, the isolate resistant to at least one antimicrobial from three different group of first line drugs tested was regarded as multidrug resistant (MDR). Extensively drug resistant (XDR) isolates were identified when the isolates were resistant to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories). Pan drug resistant (PDR) was defined as non-susceptibility to all agents in all antimicrobial categories (i.e. no agents tested were susceptible for that organism) [19].

Detection of ESBL, MBL, AmpC and KPC β-lactamases

Testing of extended spectrum β-lactamase (ESBL) producers

The initial screening test for the ESBL production was performed by using one of three antibiotics; ceftriaxone (CRO 30 µg), ceftazidime (CAZ 30 µg) or cefotaxime (CTX 30 µg) disks (HiMedia, Mumbai, India). If the zone of inhibition (ZOI) was ≤25 mm for CRO, ≤22 mm for CAZ and/or ≤27 mm for CTX, the isolate was considered a potential ESBL producer as recommended by CLSI [18]. Isolates that were suspected as ESBL-producer by screen test were tested further by combination disk test (CDT). In this test, Ceftazidime (30 µg) disks alone and in combination with clavulanic acid (ceftazidime + clavulanic Acid, 30/10 µg) disks, were applied onto a plate of Mueller Hinton Agar (MHA) which was inoculated with the test strain and then incubated in ambient air for 16-18 h of incubation at 35 ± 2 °C. Isolate that showed increase of ≥5 mm in the zone of inhibition of the combination discs in comparison to that of the ceftazidime disk alone was considered an ESBL producer [18].

Testing of metallo β-lactamase (MBL) producers

Isolates that were found non-susceptible to third generation cephalosporins (ceftazidime), imipenem or meropenem in Kirby Bauer disk diffusion method were presumptively considered MBL producers and were confirmed by the imipenem disk with ethylene diamine tetra acetic acid (EDTA) method. Briefly, the test inoculums (comparable to 0.5 McFarland standards) were prepared and transferred on to Mueller Hinton agar plates. In the combination disk test for MBL, two imipenem (IPM) disks (10 µg), a plain imipenem disk and another containing 10 µl of 0.1 M (292 µg) anhydrous EDTA (Sigma Chemicals, St. Louis, MO), were placed 20 mm apart. An increase in the zone size of more than or equal to 7 mm for imipenem-EDTA disk compared to imipenem disk alone indicated MBL producer strain as described by Yong et al. [20].

Testing of AmpC β-lactamase producers

Screening of AmpC β-lactamase production was carried out by cefoxitin disk. Isolates that yielded a zone diameter less than 18 mm (screen positive) were further subjected to confirmatory testing. Cefoxitin (30 µg) disk alone and cefoxitin (30 µg) disk containing 10 µl of 300 µg/ml PBA (Phenyl Boronic Acid) were placed at 20 mm distance. An increase in zone of inhibition by at least 5 mm around Cefoxitin disk containing Boronic acid after overnight incubation at 37 °C were considered as positive for AmpC production by the isolates [21].

Testing of Klebsiella pneumoniae carbapenemase (KPC) producers

The isolates that tested for MBL detection were also subjected to KPC production. Phenotypic test for KPC detection was performed by combination disk method. In this test, meropenem (MEM) (10 µg) disk alone and a meropenem disk containing 10 µl (300 µg/ml) 3-AminoPhenyl Boronic Acid (3-APBA) (Tokyo Chemical Co. Ltd., Japan) were placed 20 mm apart centre to centre. An increase in zone diameter of more than 5 mm around the MEM- PBA disk compared to that of
the MEM disk alone was considered positive for KPC. To exclude the AmpC overproduction in the same isolate, four disk test for differentiation of carbapenemases described by Tsakris et al. was used [22].

**Ethical consideration**
Written approval (Ref No: 129(6-11-E)/2070/71) was obtained from Institutional Review Board (IRB) of Institute of Medicine after submitting and presenting research proposal. In addition, written consent was taken from every patient or their guardian for participation into this study before enrollment.

**Data processing and analysis**
Data regarding patient demographics, HCAI types, bacterial isolates, antimicrobial susceptibilities and resistance determinants were entered in to a computer program. Data were analyzed using SPSS 20.0 version and interpreted according to frequency distribution, percentage.

**Results**

**Patient demographics**
During the study period, a total of 568 patients were admitted to the intensive care unit of our hospital. Forty six patients were transferred to another unit, 17 died and 14 patients left against medical advice within 48 h of their admission. Among 491 patients stayed more than 48 h in the ICU, male patients (280/491, 57%) were more than their female counterparts (211/491, 43%). The median age of patient was 41.4 years (IQR; 35-60) and maximum numbers of patients were from the age group 46-55 years.

**Distribution of specimens by suspected HCAI**
After clinico-bacteriological analysis, 149 clinical specimens received from 135 patients (out of 491 patients admitted to the ICU) suspected of HCAI were found to be associated with significant bacterial growth. Among specimens with significant growth, majority were from suspected hospital acquired pneumonia [(53.0%, 79/149), (overall; 16.0%, 79/491)] followed by bloodstream infections [(18.8%, 28/149), (overall; 5.7%, 28/491)], surgical site infections [(15.4%, 23/149), (overall; 4.7%, 23/491)] and urinary tract infections (12.8%,19/149), overall (3.9%, 19/491)] (Table 1).

**Distribution of bacterial isolates**
Diverse bacterial etiology was noted among HCAs (Table 2). *Acinetobacter* spp. (51, 34.9%) was the leading organism followed by *Klebsiella* spp. (37, 25.3%), *Escherichia coli* (31, 21.2%), and *Pseudomonas* spp. (24, 16.4%). Hospital acquired pneumonia were predominantly associated with *Acinetobacter* spp. (38.1%) and *Klebsiella* spp. (21.6%) while bloodstream infections were caused by *Burkholderia cepacia* (47.3%), surgical site infections caused by *Pseudomonas* spp. (31.0%) and urinary tract infections caused by *Klebsiella* spp. (42.8%). Among total 28 bloodstream infections, 19 were associated with Gram negative bacteria and remaining 9 were Gram positive bacteria (data not presented).

**Antimicrobial susceptibility pattern of isolates**

**Antibiogram of nonfermenters**
Gram negative nonfermenters were variably resistant to tested antimicrobials (Table 3). Entire isolates of *Acinetobacter* and *Burkholderia* spp. were resistant to cephalosporins, while almost 92% of *Pseudomonas* spp. were cephalosporin resistant. Resistant to fluoroquinolones was observed higher (upto100%) in *Burkholderia* spp. when compared to that in *Acinetobacter* spp. (94.2%) and *Pseudomonas* spp. (95.8%). Carbapenemases, the preferred regimens in ICU, were highly resistant in *Acinetobacter* spp. (upto86.4%) and *Pseudomonas* spp. (62.5%) but were effective against *Burkholderia* spp. (20% resistance).

**Antibiogram of Enterobacterial isolates**
In this study, entire isolates of enterobacteriaceae were resistant to third generation cephalosporins. *Klebsiella* spp. were resistant to ciprofloxacin (86.4%), gentamycin (83.7%), piperacillin tazobactam (81.0%) and imipenem (48.6%). Almost similar rates of resistance were observed in *Escherichia coli*, except for carbapenems (19.3% resistance). Although, the number of *Citrobacter* spp. was small, majority of them were resistant to cephalosporins, fluoroquinolones and aminoglycosides (Table 4).

**MDR, XDR and β-lactamase producing bacterial isolates**
Nearly 96% of the Gram negative bacterial isolates causing nosocomial infections were found multidrug resistant and 43.3% isolates were extensively drug resistant (XDR). In this study, rates of beta lactamase producing bacterial isolates was extremely high (ESBL; 43.7%, AmpC; 27.5%, MBL; 50.2% and KPC; 4.2%). *Escherichia coli* was major ESBL producer (70.9%) followed by *Citrobacter* spp. (62.5%) and *Klebsiella* spp. (59.4%). Major MBL enzyme producers were *Acinetobacter* spp. (78.8%),

---

**Table 1** Distribution of specimens by suspected Healthcare Associated Infections (HCAI)

| Type of Infections          | No. | %    | Overall incidence % |
|------------------------------|-----|------|---------------------|
| Hospital acquired pneumonia | 79  | 53.0 | 16.0                |
| Bloodstream infections       | 28  | 18.8 | 5.7                 |
| Surgical site infections    | 23  | 15.4 | 4.7                 |
| Urinary tract infections     | 19  | 12.8 | 3.9                 |
| Total                        | 149 | 100.0| 27.4                |

---
Pseudomonas spp. (62.5%) and Klebsiella spp. (48.6%). Small proportion of Klebsiella (10.8%) and Acinetobacter spp. (5.7%) were KPC producers (Table 5).

Discussion
Increased consumption of antimicrobial regimens, higher prevalence and dissemination of drug resistance among nosocomial pathogens and poor infection control strategies for prevention of healthcare associated infections are the rising problems in Nepalese hospitals [23]. The problem is several-folds high in the intensive care units where collection of severely ill patients from all over the hospital units with varieties of pathological profile and etiological agents exists. Therefore, identification of the underlying pattern of drug resistance among microorganisms in every hospital is the key to success in the appropriate treatment of patients. This issue is of interest especially in Nepalese ICUs where the highest prevalence of patients on antibiotic treatment is frequently reported.

The rate of healthcare associated infections varies globally and higher rates have been reported from developing countries [24]. Moreover, the type of hospital setting (ward or intensive care unit), patient population and the precise definition and surveillance techniques used to identify the healthcare associated infections are responsible for variable incidences [25]. Healthcare associated infections are frequent in our study as previously described by Sah et al. from same hospital [26], although they have included the patients from all sections of hospital, providing heterogeneity of the cases. However, extremely high incidences have been documented in recent reports from India (11.9-17.7%) [27, 28]. In the well

Table 2 Distribution of Bacterial isolates

| Bacterial isolates | Total number (%) |
|--------------------|------------------|
| HAP(n = 79)        | BSI(n = 28)      | SSI (n = 23) | UTI (n = 19) |
| Acinetobacter spp. (n = 51) | 37(38.1) | 3(15.7) | 7(24.1) | 4(19.0) |
| Klebsiella spp. (n = 37) | 21(21.6) | 1(5.2) | 6(20.6) | 9(42.8) |
| Escherichia coli (n = 31) | 19(19.5) | 5(26.3) | 2(6.9) | 5(23.9) |
| Pseudomonas spp.(n = 24) | 12(12.4) | 0(0.0) | 9(31.0) | 3(14.3) |
| Burkholderia cepacia (n = 14) | 6(6.2) | 9(47.3) | 0(0.0) | 0(0.0) |
| Citrobacter spp. (n = 8) | 2(2.0) | 1(5.2) | 5(17.2) | 0(0.0) |
| Total isolates (n = 165) | 97(100.0) | 19(100.0) | 29(100.0) | 21(100.0) |

Table 3 Antibiogram of Nonfermenters (n = 90)

| Antibiotics | % Resistance among bacterial isolates |
|-------------|--------------------------------------|
| Acinetobacter spp. (n = 51) | P. aeruginosa (n = 24) | Burkholderia spp. (n = 15) |
| Cotrimoxazole | 100 | - | 0 |
| Ceftazidime | 100 | 91.6 | 100 |
| Cefepime | 100 | 91.6 | 100 |
| Ciprofloxacin | 94.2 | 95.8 | 100 |
| Levofoxacin | 76.5 | 87.5 | 93.3 |
| Gentamycin | 92.2 | 62.5 | 86.6 |
| Amikacin | 84.4 | 37.5 | 67 |
| Piperacillin Tazobactam | 92.2 | 67 | 60 |
| Ampicillin Sulbactam | 92.2 | - | - |
| Cefoperazone Sulbactam | 90.2 | 67 | 86.6 |
| Imipenem | 86.4 | 62.5 | 20 |
| Meropenem | 84.4 | 62.5 | 20 |
| Polymyxin B | 0 | 0 | - |
| Colistin Sulphate | 0 | 0 | - |
| Tigecycline | 0 | - | - |

Table 4 Antibiogram of Enterobacterial isolates (n = 76)

| Antibiotics | % Resistance among bacterial isolates |
|-------------|--------------------------------------|
| Escherichia coli (n = 31) | Klebsiella spp. (n = 37) | Citrobacter spp. (n = 8) |
| Ampicillin | 100 | - | - |
| Cotrimoxazole | 64.5 | 100 | 100 |
| Cefotaxime | 100 | 100 | 100 |
| Cefepime | 100 | 100 | 100 |
| Ciprofloxacin | 90.3 | 86.4 | 100 |
| Levofoxacin | 77.4 | 72.9 | 100 |
| Gentamycin | 64.5 | 83.7 | 100 |
| Amikacin | 45.1 | 83.7 | 100 |
| Piperacillin Tazobactam | 48.3 | 81.0 | 87.5 |
| Cefoperazone Sulbactam | 48.3 | 83.7 | 87.5 |
| Imipenem | 19.3 | 48.6 | 25 |
| Meropenem | 19.3 | 48.6 | 25 |
| Polymyxin B | 0 | 0 | 0 |
| Colistin Sulphate | 0 | 0 | 0 |
| Tigecycline | 0 | 0 | 0 |
known EPIC II study by Vincent et al., 51% of the patients in ICU were found infected [1]. Another multicentre cohort study yielded the rate of infections in ICU patients around the globe to be ranging from 2.3 to 49.3% [29]. However, the higher rates in multicentre studies are due to the heterogeneous patients, study parameters, voluntary participation and reporting, as well as the variation in surveillance techniques [30].

We observed hospital acquired pneumonia (53%) to be the most common healthcare associated infection in this study, followed by bloodstream infections (18.8%), surgical site infections (15.4%) and urinary tract infections (12.8%) which are comparable to the findings of large EPIC II study [1]. Similar findings were also been reported from epidemiological study of infections in ICU population by Cosic et al. from Brazil [31] and Dasgupta et al. from India [28]. However, in a recent report, Mythri and Kashinath pointed UTI as the most common infection, followed by pneumonia and surgical site infections [27]. The site distribution of infections in various studies might be attributable to the type of ICUs and patient population. Our report broadly corroborates to the findings of earlier studies mentioned above.

Non fermentative Gram negative bacteria including enterobacteriaceae are increasingly reported as the cause of healthcare associated infections worldwide [32]. Acinetobacter species, major pathogenic organism in health-care-associated infections, was found to be the most common organisms in our ICU. Majority of the infections associated with Acinetobacter were pneumonia and surgical site infections. Similar spectrum of bacterial pathogens in healthcare associated infections in ICU has been documented by other studies too [26, 33]. However, Burkholderia cepacia was the most common bacteria isolated from bloodstream infections in our ICU. Increased use of pharmaceutical derivatives and accumulation of sicker patients with variable infections might be the reason for our shifting etiology.

Antimicrobial resistance is a recognized problem in South Asian region with high levels of resistance among Gram negative organisms reported frequently [34]. It is well known fact that resistance is due to extreme antimicrobial consumption [11], and overuse of antibiotics can be surmised as one of the factors contributing to the high rates of antimicrobial resistance in Nepal. In this study, many microorganisms found as resistant to different antimicrobial agents and in some cases to nearly all agents representing an alarming scenario in our intensive care setting. Nearly 96% of the Gram negative bacterial isolates causing nosocomial infections were found multidrug resistant, which is highest ever rate of MDR bacteria reported from our country. Earlier reports from Nepal have reported up to 95% of the nosocomial isolates as drug resistant [35, 36]. Further in this study, not only the isolates were multidrug resistant, a significant proportion (43.3%) of our isolates was extensively drug resistant (XDR). The high level of drug resistance in Gram negative isolates have been described as a result of the production of different β-lactamases, multiple efflux pumps, decreased drug uptake, and other drug modifying enzymes [37].

Gram negative non-fermenters were more resistant to antimicrobial drugs in this study. Acinetobacter isolates were found highly resistant to carbapenem (86.4%), aminoglycosides (93%) and cephalosporins (100%) groups of antibiotics which is nearly twofold high than that reported by Mishra et al. from same hospital (nearly 89% resistance in cephalosporin and 50% in carbapenem) [35]. However, the resistance rate of Gram negative non-fermenters in our study is comparable to the study of Xia et al. from China [38] and Fatima et al. from Pakistan [39]. Moreover, a SENTRY study also reported that Gram negative bacterial resistance to imipenem changed from 34.5% in 2006 to 59.8% in 2009 across the world [40]. In addition to this, the increasing emergence of highly aminoglycosides-resistant strains is also cause of major concern. Our result on amikacin resistance (up to 85%) is higher than that (54%) of previous study from same hospital [35]. Although none of the Acinetobacter strains in our study was tigecycline and colistin resistant, it has been indicated as an emerging therapeutic problem which may severely compromise the treatment of MDR Acinetobacter spp. infections [41]. This high prevalence of multi drug resistance in Acinetobacter spp. may be due to high chance of acquisition of resistance gene and their ability to persist and multiply in hospital environment [42]. On the other hand, Pseudomonas aeruginosa and Burkholderia cepacia are intrinsically resistant to several antibiotics because of the low permeability of their outer-membrane, the constitutive expression of various efflux pumps, and the production of antibiotic-inactivating enzymes (e.g., cephalosporinases) [43].

Enterobacteriaceae, including Escherichia coli, Klebsiella spp. and Citrobacter spp. were also found resistant
to multiple antibiotics. Resistance of enterobacterial strains towards cephalosporins (100%), fluoroquinolones (86.4 to 100%), aminoglycosides (45.1 to 100%) and carbapenems (19.3 to 48.6%) was considerably high when compared to the reported rates from previous studies [36, 44]. However, tigecycline and polymixins showed excellent effect against MDR Gram-negative enterobacterial isolates. High antibiotic resistance rate against commonly used antibiotics is a disadvantage for health care system in countries like Nepal as it can greatly affect patient management especially in critical care units.

Beta lactamases are the hydrolytic enzymes thwarting the functional part of β-lactam antibiotics used for the treatment of most bacterial infections. The mening state of resistance in Gram negative isolates towards the cephalosporins, carbapenems and other antibiotics could be attributed to ESBL, AmpC β-lactamase, carbapenemase producers and some other relevant underlying mechanisms [45]. In this study, the rates of beta lactamase production, including ESBL, AmpC, MBL, and KPC were alarmingly high. Escherichia coli, Klebsiella spp., Citrobacter spp., Pseudomonas spp. and Burkholderia spp. were major ESBL producers. Previously, Shrestha et al. in 2011 have also reported 28.57% of Escherichia coli, 8.33% of Klebsiella spp. and 2.38% of Pseudomonas aeruginosa were ESBL producers [46]. However, in an Indian study, the rate of ESBL production within nosocomial isolates was 50% in Escherichia coli and 67% in Klebsiella pneumoniae respectively [41]. Variations in ESBL rates may be ascribed to antibiotic prescribing habits and endemicity of pathogens harboring the genes for ESBL production. Furthermore, we detect 27.5% AmpC producing isolates, including Acinetobacter spp. (42.3%) followed by Escherichia coli (38.7%) and Klebsiella pneumoniae (32.4%) which is comparative to the previous reports of Baral et al. [47] and Khanal et al. [36] from nearby hospital. However, in an Indian study lower rate (14.2%) of AmpC producing isolates were documented [48].

High resistance of carbapenems in our study has been supported by the detection of carbapenemase enzyme in the bacterial isolates. Major bacterial isolates producing MBL were Acinetobacter spp., Pseudomonas spp., Klebsiella spp. and Burkholderia spp. Although, till date, there is no single article regarding detection of KPC from Nepal, this study attempted to find out the KPC producing bacterial isolates in ICU population. In Nepal, carbapenemase producing bacteria are poorly reported. Mishra et al. documented the rate of MBL producers to be 1.3% including Acinetobacter (4.3%), Pseudomonas (3.3%) [49], but in a study by Shrestha et al. the rate of MBL was 17.43% among nosocomial isolates including Acinetobacter (47.22%), Pseudomonas (2.38%) and of Klebsiella spp. (4.17%) [46]. The emergence of carbapenemase in Gram negative bacilli is becoming a therapeutic challenge as these enzymes possess high hydrolytic activity that leads to degradation of higher generation cephalosporins and carbapenems. Furthermore, these plasmid mediated genes have the ability spread rapidly to other species of Gram negative bacilli [50]. Therefore rapid detection of these resistance determinants is necessary to modify therapy and to initiate effective infection control to prevent their dissemination.

Limitations
We could not evaluate the risk factors and outcomes of nosocomial infections associated with drug resistant bacteria. Due to the unavailability of sufficient data from the patients without healthcare associated infections, statistical comparison between the patients with and without healthcare associated infections could not be made. Further, it was limited to a mixed adult ICU of a teaching hospital leaving other surgical and pediatric ICU patients. Furthermore, molecular characterization of the resistant phenotypes and their epidemiology would be more significant in public health perspective.

Conclusion
From this study, it becomes clear that healthcare associated infections caused by drug resistant bacteria are major problems in our ICU. Menacing state of drug resistance among Gram negative pathogens associated with these infections is particularly worrisome. It is very important to control this situation before it takes a deadly shape. Established recommendations including adequately identifying the pathogen, choosing correct antibiotics, limiting their excess use, improving resistance surveillance systems will help controlling this situation.

Abbreviations
ASM: American Society for Microbiology; BSIs: Bloodstream infection; CLSI: Clinical and Laboratory Standards Institute; ESBL: Extended spectrum β-lactamases; HAP: Hospital acquired pneumonia; HCAI: Healthcare associated infection; ICU: Intensive care unit; KPC: Klebsiella pneumoniae carbapenemase; MBL: Metallo β-lactamases; MDR: Multidrug resistant; SSI: Surgical site infection; UTI: Urinary tract infection; XDR: Extensively drug resistant

Funding
No monetary benefit was received for this study.

Availability of data and materials
Primary data regarding this report will be made available to the interested researchers upon written request.

Authors’ contributions
NPP and BMP- conceived the design of study, reviewed the literature performed necessary interventions including laboratory investigations, NPP, SPA, SKM, KP and BPR- case identification, entry and data analysis, NPP- prepared the manuscript with the help of SPA, SKM, KP, BPR and BMP. All authors read the final version of manuscript and approved for publication.

Competing interests
The authors declare that they have no competing interests.
Consen for publication
Informed consent for relevant investigations and publication of the findings were taken from every patient and co-authors.

Ethics approval and consent to participate
Written consent was taken from every patient or their visitors before participating in this study. Personal information of patients were coded and kept confidential.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Clinical Microbiology, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal. 2Department of Laboratory Medicine, Mannamohan Memorial Institute of Health Sciences, Kharma Praves Marg, Sallolimode, P.O. Box No. 15201, Kathmandu, Nepal. 3Department of Anesthesiology and Critical Care, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.

Received: 27 February 2017 Accepted: 9 June 2017

Published online: 15 June 2017

References
1. Vincent JL, Rello J, Marshall J, Silva E, Arzueta A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2233–9.
2. Vincent JL, Bihari DJ, Suter PM, Bruniing HA, White J, Nicolai-Chananon MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995; 274(6):639–44.
3. Trilla A. Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med. 1994;20(Suppl 3):S1–4.
4. Majumdar SS, Padiglione AA. Nosocomial infections in the intensive care unit. Anaesth Intens Care Med. 13(5):204–8.
5. Brunnsen N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011;1:147.
6. Meric M, Baykara N, Akyos S, Kol IO, Yilmaz G, Beyazt N, et al. Epidemiology and risk factors of intensive care unit-acquired infections: a prospective multicentre cohort study in a middle-income country. Singap Med J. 2012;53(4):260–3.
7. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlekke E, Haru GL, Goedl HM, Goossens H, Greko C, So AO, Bigdell M, Torsom G, Woodhouse W, Ombaka EA, Peralta AQ, Fong NY, Mir F, Kottuki S, Bhatta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Car O. Antibiotic resistance the need for global solutions. The Lancet Infectious Diseases. 2013;13(12):1057–98.
8. Vasudev A, Memon B, Mulhaphdadhyay A, Li J, Tampoby PA. The costs of nosocomial-resistant gram-negative intensive care unit infections among patients with the systemic inflammatory response syndrome—a propensity matched case control study. Antimicrob Resist Infect Control. 2015;4(1):1–8.
9. Horcajada JP, Belvis F, Castells X, Grau S, Riu M, Morales E, et al. Hospital costs of nosocomial multi-drug-resistant Pseudomonas aeruginoa acquisition. BMC Health Serv Res. 2012;12.
10. Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care. 2001;5(4):189–95.
11. Bjurugubba DK. Antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents. 24(2):105–10.
12. Fraimow HS, Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin. 27(1):163–205.
13. Rahal JJ. Antimicrobial resistance among and therapeutic options against gram-negative pathogens. Clin Infect Dis. 2009;49(Suppl 1):S4–10.
14. Yamamoto M, Pop-Vicas AE. Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have? Crit Care. 2014;18(3):1–8.
15. Ruppé E, Woerther P-L, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacteria. Ann Intensive Care. 2015;5:21.
16. Isenberg HD. Clinical Microbiology procedure handbook, vol. 1. 2nd ed. Washington DC: American Society for Microbiology; ASM press; 2004.
17. Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-cather-related infection. N Engl J Med. 1977; 296(23):1305–5.
18. CLSI. Performance standards for antimicrobial disk susceptibility tests, vol. M2-A11. Wayne: Clinical and Laboratory Standards Institute; 2012.
19. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.
20. Dong Y, Lee K, Yum JH, Shin HB, Rosolfini GM, Chong T. Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of pseudomonas spp. and acinetobacter spp. J Clin Microbiol. 2002; 40(10):3798–801.
21. Courdon PE. Inhibitor-based methods for detection of plasmid mediated AmpC B-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. J Clin Microbiol. 2005;43:5.
22. Tsakris A, Poublou A, Pournaras S, Voulgari E, Vrioni G, Themeli-Digalaki K, et al. A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J Antimicrob Chemother. 2010;65(8):1664–71.
23. Shrestha S, Tada T, Miyoshi-Akiyama T, Obara H, Shimada K, Satou K, et al. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii isolates in a university hospital in Nepal reveals the emergence of a novel epidemic clonal lineage. Int J Antimicrob Agents. 2015;45(6):525–31.
24. Allegranzi B, Bagheri Nejad S, Combescura C, Grahnans W, Attar H, Donalson L, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet (London, England). 2011;377(9761):228–41.
25. Gastmeier P, Sohr D, Just HM, Naasauer A, Dachner F, Ruden H. How to survey nosocomial infections. Infect Control Hosp Epidemiol. 2000;21(6):366–70.
26. Sah M, Mishra S, Ohora H, Kikae T, Shichan J, Rials B. Nosocomial bacterial infection and antimicrobial resistant pattern in a tertiary care hospital in Nepal. J Int Med. 2015:38(1).
27. Myrihi H, Kashnath K. Nosocomial infections in patients admitted in intensive care unit of a tertiary health center, India. Ann Med Health Sci Res. 2014;4(9):378–41.
28. Dasgupta S, Das S, Chawhan NS, Hazra A. Nosocomial infections in the intensive care unit: Incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India. Indian J Crit Care Med. 2015;19(1):14–20.
29. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28(2):108–21.
30. Toufen C Jr, Hovnanian AL, Franca SA, Carvalho CR. Prevalence rates of infection in intensive care units of a tertiary teaching hospital. Rev Hosp Clin Fac Med Sao Paulo. 2003;58(5):254–9.
31. Ćosić Gorana DJ, Smiljana R, Ristic M, Ikonić N. Nosocomial infections and microbiological agents in an intensive care unit. Arch Biol Sci Belgrade. 2012;64(4):8.
32. Mehrad B, Clark NM, Zhanell GG, Lynch JP 3rd. Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. Chest. 2015;147(5):1413–21.
33. Habibi S, Wig N, Agnawa S, Sharma SK, Lohda R, Pandey RM, et al. Epidemiology of nosocomial infections in medicine intensive care unit at a tertiary care hospital in northern India. Trop Dr. 2008;38(4):233–5.
34. Khanal S, Joshi DR, Bhatta DR, Devkota U, Pokhrel BM. beta-lactamase-producing Acinetobacter calcoaceticus baumannii complex and methicillin-resistant Staphylococcus aureus–Acinetobacter calcoaceticus baumannii complex and methicillin-resistant Staphylococcus aureus. BMC Res Notes. 2013;6:222.
35. Isenberg HD. Clinical Microbiology procedure handbook, vol. 1. 2nd ed. Washington DC: American Society for Microbiology; ASM press; 2004.
36. Bhatia R, Narain BP, Pokhrel BM. Emerging threat of multidrug resistant bugs–Acinetobacter calcoaceticus baumannii complex and methicillin-resistant Staphylococcus aureus. BMC Res Notes. 2013;6:98.
37. Khanal S, Joshi DR, Bhatta DR, Devkota U, Pokhrel BM. beta-lactamase-producing multidrug-resistant bacterial pathogens from tracheal aspirates of intensive care unit patients at national institute of neurological and allied sciences, Nepal. ISRN Microbiol. 2013;2013:847560.
38. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Ann J Med. 2006;119(6 Suppl 1):S3–10. discussion S62-70.
39. Xie DS, Xiong W, Lai RP, Liu L, Gan XM, Wang XH, et al. Ventilator-associated pneumonia in intensive care units in Hubei Province, China: a multicentre prospective cohort survey. J Hosp Infect. 2011;78(4):284–8.
39. Fatima A, Naqvi SB, Khaliq SA, Perveen S, Jabeen S. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa isolated from patients of lower respiratory tract infections. SpringerPlus. 2012;1(1):70.

40. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother. 2011;66(9):2070–4.

41. Joseph NM, Sista S, Dutta TK, Badhe AS, Rasitha D, Parija SC. Ventilator-associated pneumonia in a tertiary care hospital in India: role of multi-drug resistant pathogens. J Infect Dev Ctries. 2010;4(4):218–25.

42. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–82.

43. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis. 1998;27(Suppl 1):S93–9.

44. Mishra SK, Awal BK, Kattel HP, Acharya J, Gyawali P, Bhatt CP, et al. Drug resistant bacteria are growing menace in a University Hospital in Nepal. Am J Epidemiol Infect Dis. 2014;2(1):19–23.

45. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012;27(2):128–42.

46. Shrestha S, Kattel HP, Mishra SK, Dahal RK, Ohara H, Pokhrel BM. Prevalence of nosocomial lower respiratory tract infections caused by Multidrug resistance pathogens. J Inst Med. 2011;33:8.

47. Baral P, Neupane S, Shrestha B, Ghimire KR, Marasini BP, Lekhak B. Clinical and microbiological observational study on AmpC beta-lactamase-producing Enterobacteriaceae in a hospital of Nepal. Braz J Infect Dis. 2013;17(2):256–9.

48. Grover N, Sahni AK, Bhattacharya S. Therapeutic challenges of ESBLS and AmpC beta-lactamase producers in a tertiary care center. Med J Armed Forces India. 2013;69(1):4–10.

49. Mishra SK, Acharya J, Kattel HP, Koirala J, Rijal BP, Pokhrel BM. Metallo-beta-lactamase producing gram-negative bacterial isolates. J Nepal Health Res Counc. 2012;10(2):208–13.

50. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11(5):355–62.